Incannex Healthcare Inc. (IXHL) — Incannex Healthcare, whose psychedelic program PSX-001 is an oral synthetic psilocybin in Phase 2 for generalized anxiety disorder, announced a 1-for-30 reverse stock split effective February 26 to regain Nasdaq minimum-price compliance.
The split reduced shares outstanding from roughly 358 million to about 12 million. The move reflected continued financing and listing pressure on small-cap psychedelic developers.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.